Observation the clinical efficacy of Apatinib combined with the second line chemotherapy in advanced gas-tric cancer with positive AFP
10.3969/j.issn.1006-5725.2018.05.028
- VernacularTitle:阿帕替尼联合二线化疗方案在晚期甲胎蛋白阳性胃癌中的临床疗效观察
- Author:
Jing KUANG
1
;
Jiamei YANG
Author Information
1. 郑州大学第二附属医院肿瘤科 郑州450000
- Keywords:
gastric cancer with afp positive;
apatinib;
second line chemotherapy;
clinical efficacy
- From:
The Journal of Practical Medicine
2018;34(5):810-813
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the difference of clinical curative effect of Apatinib combined with second line chemotherapy between AFP positive gastric cancer and AFP negative gastric cancer.Methods The da-ta of 78 patients that met the inclusion criteria with advanced gastric cancer from January 2015 to June 2017 were collected from the Second Affiliated Hospital of Zhengzhou University.According to the blood serum AFP levels be-fore treatment(including chemotherapy,surgery)the patients were divided into the AFP positive group(AFPGC) and the AFP negative group(NAFPGC),excluding the impact of other factors.Analysing the difference of the clin-ical effect with apatinib combined with second line chemotherapy in the two groups. Results Getting rid of other factors that may affect the efficacy of chemotherapy,we administered apatinib combined with docetaxel or irinote-can regimen as second line therapy for gastric cancer.The AFP positive group was treated for 2 cycles,4 cycles,in which ORR and DCR were significantly better than that of the AFP negative group(P<0.05).The OS of the AFP positive group and the AFP negative group was 5.5 months,6 months(P = 0.747). No significant adverse reac-tions occurred in the two groups. Conclusion Chemotherapy curative effect of the AFP positive group of apatinib combined with docetaxel or irinotecan is obviously better than that of the AFP negative group in short term,but no obvious difference in long term effect.
